The intraocular pressure reducing effect of Latanoprost has been shown to be additive to that of beta-adrenergic antagonists (timolol), adrenergic agonists (dipivalyl epinephrine), carbonic anhydrase inhibitors (acetazolamide), and at least partly to cholinergic agonist (pilocarpine) in short term clinical trials.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
